(Investorideas.com Newswire) a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc.(Nasdaq:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune ...

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review (Investorideas.com Newswire) a leading investment platform for retail investors reports breaking Medical Tech Stock news for Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company develop ...

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review Accessibility StatementSkip Navigation About the Hemopurifier® The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EV ...

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) on the Move – Morning High of $2.09 March 13, 2026 – (Investorideas.com Newswire) Reports Breaking Medical Tech Stock news - Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The stock is building on yesterday’s gains, currently trading at $1.96, up 0.23, gaining over 13%. Aethlon has a morning high of $2.09 as of this report.  Aethlon Me ...

Aethlon Medical Conference Summary Company Overview - **Company Name**: Aethlon Medical - **Ticker Symbol**: AEMD (NasdaqCM) - **Industry**: Life Sciences, specifically focused on medical devices for oncology and virology Key Points and Arguments Product Description - **Lead Asset**: Hemopurifier, a medical device designed to remove harmful viruses and cancerous particles (exosomes) from the bloodstream [3][4] - **Mechanism**: The device connects to existing blood pumping mechanisms (e.g., dialysis machines) and filters blood to remove harmful particles [3][4][7] - **FDA Designation**: Received Breakthrough Device designation for life-threatening viruses and oncologic situations with no prescribed therapy [4] Clinical Focus - **Primary Focus**: Oncology, with ongoing clinical trials in Australia [4][5] - **Current Trial**: A safety trial involving three cohorts of patients, aiming to assess the Hemopurifier's effectiveness in conjunction with chemotherapy drugs like Keytruda and Opdivo [10][11] - **Market Potential**: Keytruda has a market size of approximately $25 billion, with the potential to improve treatment efficacy for the two-thirds of patients who do not respond to current therapies [12][13] Milestones and Progress - **Upcoming Milestones**: - Approval from the Data Safety Monitoring Board to proceed to the third cohort [14][15] - Data release from the second cohort and overall trial results expected in the next six months [16][24] - **Current Status**: Completed the first cohort and treated all patients in the second cohort [14][15] Financial Position - **Cash Position**: Approximately $7 million in cash with a burn rate of $1.5 million per quarter [26] - **Funding Strategy**: Engaging with investment banks for potential strategic partnerships to support the next phases of trials [34] Research and Development - **Future Applications**: Exploring the Hemopurifier's potential in treating autoimmune diseases and chronic kidney disease, while maintaining a primary focus on oncology [19][20] - **Simplified System Development**: Investigating a more user-friendly blood pumping system that could enhance the Hemopurifier's accessibility [28][29] Market Insights - **Differentiation**: The Hemopurifier is the only product that specifically removes extracellular vesicles (EVs), which could significantly improve patient outcomes in cancer treatment [50] - **High-Risk Investment**: Acknowledgment of the high-risk nature of the investment, but with potential for significant returns if successful [40] Regulatory Considerations - **Trial Location**: Conducting trials in Australia due to favorable medical practices and financial incentives, such as a reimbursement of 43% on trial costs [21][22] - **Regulatory Pathway**: Plans to apply for regulatory approval in both Australia and the U.S. upon completion of the trial [23] Additional Important Information - **Patient Treatment**: 173 Hemopurifier treatments have been conducted across 44 patients, with no serious adverse events reported [37] - **Market Opportunity**: The oncology market is vast, and even a small improvement in treatment efficacy could lead to significant patient benefits [40][48] This summary encapsulates the key aspects of Aethlon Medical's conference, highlighting the company's focus on innovative medical devices, ongoing clinical trials, financial health, and market potential.

Core Viewpoint - Aethlon Medical, Inc. (NASDAQ: AEMD) is exploring strategic opportunities with the assistance of Maxim Group LLC, which has led to a notable increase in stock price and trading volume [3][4][5]. Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier, a device aimed at treating cancer and life-threatening infectious diseases [8][9]. - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [9]. Stock Performance - The stock price of Aethlon Medical increased by 4.81%, trading at $1.7300, with a day's high of $1.94 and a trading volume exceeding 859,000 shares [3][4]. Strategic Initiatives - The company has engaged Maxim Group LLC as its exclusive financial advisor to evaluate various strategic alternatives, including partnerships, mergers, and acquisitions [4][5]. - CEO James Frakes indicated that the company is actively pursuing development activities, including the completion of the second cohort of an Australian oncology trial [6]. Clinical Development - Aethlon Medical has completed the second cohort of its oncology trial in Australia, with safety data set to be submitted for review [6].

Core Insights - Aethlon Medical, Inc. (NASDAQ: AEMD) is evaluating strategic opportunities and has engaged Maxim Group LLC as its exclusive financial advisor for this process [3][4] - The engagement with Maxim follows preliminary interest in potential strategic transactions, including partnerships, mergers, and acquisitions [4] - The company continues its development activities, having completed the second cohort of an Australian oncology trial, with safety data to be submitted for review [5] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [8] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful extracellular vesicles (EVs) from biological fluids [8] - The device is designated as a Breakthrough Device by the FDA for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [8]

Core Insights - Aethlon Medical is evaluating strategic opportunities and has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process [1] - The company has received preliminary interest regarding potential strategic opportunities, including partnerships, mergers, and acquisitions [1] - Aethlon has completed the second cohort of its Australian oncology trial, with safety data to be submitted for review [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company focused on developing products to treat cancer and life-threatening infectious diseases [1] - The company is advancing the Hemopurifier, a novel platform designed to selectively remove pathogenic targets from biological fluids [1] Financial Advisory Engagement - Maxim Group LLC, founded in 2002, is a full-service investment bank providing a range of financial services, including investment banking and equity research [1] - The engagement with Maxim is part of Aethlon's ongoing efforts to assess opportunities for the company and its shareholders [1]

Core Insights - Aethlon Medical, Inc. will present at the Life Sciences Investor Forum on March 12, 2026, with CEO and CFO Jim Frakes leading the presentation [1][2]. Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases [7]. - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, utilizing a unique platform that combines plasma separation, size exclusion, and affinity binding [5]. Product Highlights - The Hemopurifier has received U.S. Food and Drug Breakthrough Device Designation for treating advanced or metastatic cancer unresponsive to standard therapies and for addressing life-threatening viruses without approved therapies [6]. - The device has shown efficacy in both in vitro studies and human subjects, indicating its potential in cancer treatment and infectious diseases [5]. Recent Developments - Clinical Progress: The second cohort of the Australian oncology trial is actively progressing, demonstrating continued clinical execution [8]. - Scientific Advancement: Ongoing research on extracellular vesicles (EVs) includes data on Long COVID, supporting the Hemopurifier's potential as a multi-indication therapeutic approach [8]. - Technology Development: Evaluation of Hemopurifier compatibility with simplified blood treatment systems is ongoing to broaden clinical applications [8]. - Operational Efficiency: The company has maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to the previous year [8].

Aethlon Medical Conference Summary Company Overview - **Company**: Aethlon Medical (NasdaqCM:AEMD) - **Focus**: Development of medical devices for treating cancer and life-threatening infectious diseases, specifically the Hemopurifier [2][3] Key Points and Arguments Hemopurifier Device - **Description**: A medical device designed to remove infectious viruses and cancerous particles (exosomes) from the bloodstream, compatible with various blood-pumping devices [3][4] - **Primary Focus**: Oncology, particularly in patients with solid tumors who do not respond to anti-PD-1 therapies like Keytruda or Opdivo [6][10] Clinical Trials and Safety - **Historical Use**: The Hemopurifier has treated a total of 44 patients across 173 sessions, with a good safety profile and minor side effects [7][10] - **Current Study**: A safety and feasibility study involving three cohorts, with the first cohort completed successfully, and the second cohort currently in the safety follow-up phase [10][11] - **Upcoming Milestones**: Data Safety Monitoring Board meeting in March to assess the second cohort, followed by data analysis from a central lab [11][37] Regulatory and Market Strategy - **Trial Location**: Conducting trials in Australia due to favorable tax rebate programs (43% rebate) and established relationships with local investigators [12] - **Regulatory Pathway**: Plans to engage with both U.S. FDA and Australian TGA for future trials, with Breakthrough Device designations already in place [12][33] Financial Position - **Cash Position**: Approximately $7 million in cash with a monthly burn rate of $500,000, providing a runway through the current trial [30][32] - **Funding Strategy**: Access to an at-the-market offering to raise an additional $1.8 million [30] Market Potential - **Addressable Market**: The oncology market is substantial, with Keytruda alone generating $25 billion annually. Aethlon aims to carve out a niche by focusing on extracellular vesicles [35] Recruitment and Operational Changes - **Patient Recruitment**: Enhanced recruitment strategies through partnerships with Trialfacts and Dedicated, leading to a pipeline of pre-screened patients for upcoming cohorts [16][18] Competitive Differentiation - **Unique Approach**: The Hemopurifier's method of removing extracellular vesicles is distinct from traditional therapies like monoclonal antibodies and vaccines, potentially offering a cleaner safety profile [41][46] Additional Important Content - **SLAM Platform**: Early studies are being conducted to assess compatibility with a new SLAM system, which could simplify the treatment process and expand the patient base [13][15] - **Future Catalysts**: Key upcoming events include the Data Safety Monitoring Board meeting, data disclosures from the University of Sydney, and completion of the third cohort [36][38] This summary encapsulates the critical insights from the Aethlon Medical conference, highlighting the company's innovative approach, clinical progress, and strategic positioning within the oncology market.